175 related articles for article (PubMed ID: 17851231)
1. Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.
Corna D; Sangalli F; Cattaneo D; Carrara F; Gaspari F; Remuzzi A; Zoja C; Benigni A; Perico N; Remuzzi G
Am J Nephrol; 2007; 27(6):630-8. PubMed ID: 17851231
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.
Kostapanos MS; Milionis HJ; Saougos VG; Lagos KG; Kostara C; Bairaktari ET; Elisaf MS
J Cardiovasc Pharmacol Ther; 2007 Dec; 12(4):292-7. PubMed ID: 18172223
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects.
Sironi L; Gianazza E; Gelosa P; Guerrini U; Nobili E; Gianella A; Cremonesi B; Paoletti R; Tremoli E
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):598-603. PubMed ID: 15681303
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Gazi I; Kostara C; Bairaktari ET; Elisaf M
J Clin Pharmacol; 2006 Nov; 46(11):1337-43. PubMed ID: 17050799
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosuvastatin on capillary filtration of albumin and blood pressure in rats with streptozotocin-induced diabetes.
Tarhzaoui K; Valensi P; Boulakia FC; Lestrade R; Albertini JP; Behar A
Diabetes Res Clin Pract; 2008 Jun; 80(3):335-43. PubMed ID: 18406000
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.
Whaley-Connell A; DeMarco VG; Lastra G; Manrique C; Nistala R; Cooper SA; Westerly B; Hayden MR; Wiedmeyer C; Wei Y; Sowers JR
Am J Nephrol; 2008; 28(1):67-75. PubMed ID: 17914247
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
Ott C; Ritt M; Titze SI; Schäufele T; Schmieder RE
J Nephrol; 2009; 22(5):675-81. PubMed ID: 19810001
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin preserves renal structure following unilateral ureteric obstruction in the neonatal rat.
Mazzei LJ; García IM; Altamirano L; Docherty NG; Manucha W
Am J Nephrol; 2012; 35(2):103-13. PubMed ID: 22212364
[TBL] [Abstract][Full Text] [Related]
10. Human proximal tubular epithelium actively secretes but does not retain rosuvastatin.
Verhulst A; Sayer R; De Broe ME; D'Haese PC; Brown CD
Mol Pharmacol; 2008 Oct; 74(4):1084-91. PubMed ID: 18612079
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Krämer S; Kron S; Wang-Rosenke Y; Loof T; Khadzhynov D; Morgera S; Kawachi H; Shimizu F; Martini S; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F801-11. PubMed ID: 18216152
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
Verhulst A; D'Haese PC; De Broe ME
J Am Soc Nephrol; 2004 Sep; 15(9):2249-57. PubMed ID: 15339974
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
14. Retention of albumin in the circulation is governed by saturable renal cell-mediated processes.
Koltun M; Comper WD
Microcirculation; 2004 Jun; 11(4):351-60. PubMed ID: 15280074
[TBL] [Abstract][Full Text] [Related]
15. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
[TBL] [Abstract][Full Text] [Related]
16. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus.
Schäfer A; Fraccarollo D; Vogt C; Flierl U; Hemberger M; Tas P; Ertl G; Bauersachs J
Biochem Pharmacol; 2007 May; 73(9):1367-75. PubMed ID: 17270148
[TBL] [Abstract][Full Text] [Related]
17. An overview of statin-associated proteinuria.
Tiwari A
Drug Discov Today; 2006 May; 11(9-10):458-64. PubMed ID: 16635810
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats.
Loch D; Levick S; Hoey A; Brown L
J Cardiovasc Pharmacol; 2006 Mar; 47(3):396-404. PubMed ID: 16633082
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin beneficially alters the glomerular structure of kidneys from spontaneously hypertensive rats (SHRs).
de Barros EP; Garcia-Pinto AB; Machado PY; dos Santos Pereira MJ; de Carvalho JJ
J Mol Histol; 2011 Aug; 42(4):323-31. PubMed ID: 21670990
[TBL] [Abstract][Full Text] [Related]
20. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Savarese G; Musella F; Volpe M; Paneni F; Perrone-Filardi P
Int J Cardiol; 2013 Sep; 167(6):2482-9. PubMed ID: 22633671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
